Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Unlocking a genetic model of NK-cell transformation

Olli Dufva

Blood (2024) 143 (24): 2443–2444.

https://doi.org/10.1182/blood.2024024550

Published: 2024

Journal Articles

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2023-189570

Published: 2023

Journal Articles

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Blood (2023) 142 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2023-185630

Published: 2023

Journal Articles

Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells

Hanna Duàn, Olli Dufva, Emmi Jokinen, Hanna Lähteenmäki, Jay Klievink, Jonas Bouhlal, Jason Theodoropoulos, Heikki Kuusanmäki, Tanja Ruokoranta, Pauliina Rumm, Dean Anthony Lee, Esa Pitkänen, Tomi P Mäkelä, Kimmo Porkka, Oscar Brück, Satu Mustjoki

Blood (2023) 142 (Supplement 1): 66.

https://doi.org/10.1182/blood-2023-174037

Published: 2023

Journal Articles

High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers

Jonas Bouhlal, Petra Nygren, Emmi Jokinen, Essi Laajala, Aleksandr Ianevski, Diogo Dias, Jay Klievink, Hanna Lähteenmäki, Hanna Duàn, Khalid Saeed, Dean Anthony Lee, Tero Aittokallio, Olli Dufva, Satu Mustjoki

Blood (2023) 142 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2023-174386

Published: 2023

Journal Articles

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Blood (2023) 141 (13): 1610–1625.

https://doi.org/10.1182/blood.2021011094

Published: 2023

Includes: Supplemental data

Journal Articles

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 101–103.

https://doi.org/10.1182/blood-2022-158694

Published: 2022

Journal Articles

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki

Blood (2022) 140 (Supplement 1): 799–800.

https://doi.org/10.1182/blood-2022-165247

Published: 2022

Journal Articles

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Blood (2022) 140 (Supplement 1): 8343–8344.

https://doi.org/10.1182/blood-2022-167535

Published: 2022

Journal Articles

A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

Petra Johanna Nygren, Aino Häkkinen, Daehong Kim, Timo Jarvinen, Fumihiro Ishida, Stefania Bortoluzzi, Andrea Binatti, Vanessa Rebecca Gasparini, Renato Zambello, Mikko Myllymäki, Seishi Ogawa, Yusuke Okuno, Hiroshi Kimura, John Chan, Olli Dufva, Satu Mustjoki, Matti Kankainen

Blood (2022) 140 (Supplement 1): 6390–6391.

https://doi.org/10.1182/blood-2022-162285

Published: 2022

Journal Articles

Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Leo Meriranta, Selma Sorri, Sadia Zafar, Xiaonan Liu, Eerika Sahlberg, Olli Dufva, Helka Göös, Marja-Liisa Karjalainen-Lindsberg, Markku Varjosalo, Marko Hyytiäinen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 5889–5890.

https://doi.org/10.1182/blood-2022-166768

Published: 2022

Journal Articles

Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma

Sara Gandolfi, Olli Dufva, Jani Huuhtanen, Olga Dashevsky, Jay Klievink, Jonas Bouhlal, Michal Sheffer, Matti Kankainen, Ricardo De Matos Simoes, Satu Mustjoki, Constantine S. Mitsiades

Blood (2021) 138 (Supplement 1): 732.

https://doi.org/10.1182/blood-2021-153925

Published: 2021

Journal Articles

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Blood (2021) 138 (Supplement 1): 801.

https://doi.org/10.1182/blood-2021-147150

Published: 2021

Journal Articles

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Jani Huuhtanen, Jason Theodoropoulos, BSc, Rebecca Warfvinge, MSc, Andreas Burchert, MD, Tiina Kasanen, Jay Klievink, MSc, Shady Adnan Awad, MD, Olli Dufva, MD, Mette Ilander, PhD, Taina Jaatinen, Ulla Olsson-Strömberg, MD PhD, Henrik Hjorth-Hansen, MD, Göran Karlsson, PhD, Harri Lähdesmäki, PhD, Anna Kreutzman, PhD, Satu Mustjoki, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139134

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Olli Dufva, Khalid Saeed, Sara Gandolfi, MD, Michal Sheffer, PhD, Jay Klievink, Petri Pölönen, MSc, Tiina Hannunen, Mette Ilander, PhD, Pekka Ellonen, BSc, Matti Kankainen, PhD, Dean Anthony Lee, MD PhD, Constantine S. Mitsiades, MD PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 3597.

https://doi.org/10.1182/blood-2019-129837

Published: 2019

Journal Articles

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Sara Gandolfi, MD, Michal Sheffer, PhD, Olli Dufva, Khalid Saeed, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Jennifer Roth, Rizwan Romee, MD PhD, Satu Mustjoki, MD PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 620.

https://doi.org/10.1182/blood-2019-130793

Published: 2019

Journal Articles

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Helena Hohtari, MD, Shady Awad, MD, Olli Dufva, Swapnil Potdar, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Satu Mustjoki, MD PhD, Kimmo Porkka, MD PhD

Blood (2018) 132 (Supplement 1): 3975.

https://doi.org/10.1182/blood-2018-99-110610

Published: 2018

Journal Articles

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

Olli Dufva, Jay Klievink, Khalid Saeed, Matti Kankainen, PhD, Mette Ilander, PhD, Tiina Hannunen, Sonja Lagström, Pekka Ellonen, BSc, Dean Anthony Lee, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 732.

https://doi.org/10.1182/blood-2018-99-117985

Published: 2018

Journal Articles

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Shady Awad, MD, Matti Kankainen, PhD, Olli Dufva, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2018-99-111602

Published: 2018

NARROW

Unlocking a genetic model of NK-cell transformation

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation

Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells

High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia

Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

Oncogenic Mutational Disruption of KLHL6 Dimers Fuels B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma

Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS

Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo

Genome-Scale CRISPR Screens Identify Essential Genes for Sensitivity to Natural Killer Cells in Hematological Malignancies

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only